What should the RPS do to ensure the professional autonomy of its members isn’t adversely affected by the working conditions imposed by employers? Candidates explain what they think the Royal Pharmaceutical Society should do to ensure the professional autonomy of its members isn’t adversely affected by the working conditions imposed by employers.…
Insulin and metformin in combination cut mortality in type 2 diabetes People with type 2 diabetes who take metformin with insulin have a reduced risk of major adverse cardiac events and death compared with those treated with insulin alone, according to a study carried out at Cardiff University and published in PLoS One on 6 May 2016.…
Risk of heart failure from saxagliptin and sitagliptin no higher than for other antidiabetics New users of dipeptidyl peptidase-4 inhibitors saxagliptin and sitagliptin are not at increased risk of heart failure compared with users of other antidiabetic drugs, a study commissioned by the US Food and Drug Administration has found.…
Diabetes drugs with antioxidant properties linked to spread of cancer Some recent treatments for diabetes may enhance the spread of cancer, suggest the results of a study conducted in mice.…
EMA to review canagliflozin over amputation risks The European Medicines Agency has announced that it is reviewing the diabetes drug canagliflozin after an ongoing clinical trial found it may increase the rate of lower limb amputations.…
Metformin cuts cardiovascular risk over sulfonylureas Metformin reduces the risk of adverse cardiovascular outcomes in patients with type 2 diabetes compared with sulfonylurea monotherapies, a study shows.…
Diabetes has quadrupled across the globe, WHO says The number of adults living with diabetes across the world has increased four-fold since 1980, but access to insulin is a big problem in poor nations, says the World Health Organization (WHO).…
Antidiabetic incretin-based drugs not linked to heart failure risk Patients who take incretin-based drugs are no more likely to have heart failure than those taking oral antidiabetic drug combinations, study finds.…
RPS survey sheds light on day-to-day role of pharmacists RPS survey highlights the key services and interactions provided by pharmacists across the NHS each week.…
ACE inhibitors and ARBs equally effective in diabetics Researchers find ACE inhibitors and ARBs produce similar outcomes in analysis of more than 100,000 diabetic patients.…
